FDA Approves Imaavy for wAIHA – Thalassaemia International Federation
Thalassaemia International Federation shared a post on LinkedIn:
”For the first time, people living with warm autoimmune haemolytic anaemia (wAIHA) have a treatment specifically approved for their disease by the U.S. Food and Drug Administration (FDA).
Imaavy (nipocalimab-aahu) has been approved for patients aged 12 years and older who are currently receiving or have previously received corticosteroids.
wAIHA is a rare and potentially life-threatening condition in which harmful antibodies attack and destroy the body’s red blood cells.
Until now, patients have depended largely on corticosteroids and other broad immunosuppressive therapies, often while facing relapses, debilitating fatigue, and serious complications.
In the pivotal ENERGY study, approximately three times as many participants receiving the approved dose achieved a durable haemoglobin response as those receiving placebo — 23.7 percent versus 7.7 percent.
Haemoglobin levels improved as early as the first week, alongside encouraging findings regarding fatigue and corticosteroid reduction.
TIF and the Rare Anaemias International Network (RAIN) warmly welcome this important development for the rare anaemias community.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 03:13Sumyea Kabir: Pre-Analytical Quality in Phlebotomy – Preventing In Vitro Hemolysis
-
Oct 20, 2026, 02:37M. Sekip Altunkan: Can Anticoagulation Be Safely Stopped After AF Ablation?
-
Oct 20, 2026, 02:26Ahmed Ammar: Managing VT Recurrence Post-Ablation
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease